Table 1

Case series overview: clinical presentation, treatment modality, best tumour marker, radiological response and time to progression*.

CaseAgeClinical presentationLine of treatmentTreatment typeBest CA-125 responseBest radiological responseTTP (mo)Time from diagnosis to last follow-up (mo)
128Abdominalpain and 15 cm pelvic mass1st Optimal tumour debulking, 4 cis-pem, pelvic RT and brachytherapyNKSD23
2nd Surgery, 4 cis-pemNKSD30
3rd 8 carbo-pem38→21SD17
4th 2.8 years PI3K-mTOR inhibitor217→32cPR34
5th 6 mo PARP-AKT inhibitor200→69SDAWD156
219Vaginal bleeding, abdominal pain and distension1st 4 cis-pemNKSD35
2nd 4 cis-pemNKSD11
3rd 2 mo HDAC inhibitorNKSD5
4th 15 mo PI3K-mTOR inhibitor200→172SDAWD123
  • *TTP, time to progression; mo, months; SD, stable disease; cPR, confirmed partial response; AWD, alive with disease; RT, radiotherapy; cis, cisplatin; carbo, carboplatin; pem, pemetrexed; PI3K, phosphatidyl-3-kinase; mTOR, mammalian target of rapamycin; PARP, poly(ADP)-ribose polymerase; HDAC, histone deacetylase; NK, not known.